{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Enpoints', 'Safety', 'To evaluate safety and tolerability of', 'Incidence of adverse events', 'UMEC/VI (62.5/25 mcg once daily),', 'UMEC (62.5 mcg once daily) and', 'salmeterol 50', 'mcg twice daily)', 'Exploratory', 'To explore the effect of UMEC/VI', 'Rate of mild, moderate or severe', '(62.5/25 mcg once daily), UMEC', 'exacerbations', '(62.5 mcg once daily) with salmeterol', '(50 mcg twice daily) on rate of COPD', 'Rate of moderate or severe', 'exacerbation', 'exacerbation', 'To compare albuterol/salbutamol use', 'Rescue albuterol/salbutamol use,', 'captured in the eDiary with the', '(percentage of rescue-free days and', 'electronic metered dose inhaler (eMDI)', 'mean number of Inhalations/day)', 'device', 'captured by the eMDI device over 24', 'weeks as data allow', 'To explore the effect of UMEC/VI', 'Change from baseline in physical', '(62.5/25 mcg once daily), UMEC (62.5', 'activity', 'mcg once daily) with salmeterol (50', 'mcg twice daily) on physical activity', 'To investigate the CID composite', 'To compare physical activity levels,', 'endpoint ability to predict short term', 'ER-S, rescue medication use,', 'outcomes', 'exacerbations and mortality in subjects', 'with and without a CID', '4.', 'STUDY DESIGN', '4.1.', 'Overall Design', 'This is a multi-centre, randomized, double blind, double-dummy, 3-arm parallel group', 'study. Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation', 'powder (62.5/25 mcg once daily) administered via the ELLIPTATM dry powder inhaler, or', 'UMEC (62.5 mcg once daily) administered via the ELLIPTATM or salmeterol (50 mcg', 'BID) administered via the DISKUS.', 'There will be a total of 5 clinic visits and one follow-up phone call (Visit 6). A pre-', 'screening visit (Visit 0) may be required in order to administer the informed consent', \"before any changes are made to the subject's current medication regimen. If no changes\", 'in medication are required, V0 (pre-screening) and V1 (screening) may be conducted on', 'the same day. Inhaled long-acting muscarinic antagonist (LAMA) or long-acting beta2-', 'agonist (LABA) and/or albuterol/salbutamol as needed (rescue medication) are not', 'exclusionary prior to Screening or during the run-in.', '19']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Eligible subjects at Screening Visit 1 will be current or former smokers, at least 6 weeks', 'ICS and ICS/LABA free with an FEV1 post-albuterol/salbutamol of >30% to 80%', 'predicted normal and a FEV1/FVC <0.7 and a CAT score >10.', 'Subjects using inhaled LAMA or LABA medication must withhold their morning dose', 'prior to Screening spirometry. Subjects who meet all other eligibility criteria at Screening', 'will enter a run-in period for 4 weeks. During the run-in period, subjects will continue', 'with their inhaled LAMA or LABA medication. In addition, subjects will be provided', 'with short acting albuterol/salbutamol as needed for relief of COPD symptoms (rescue', 'medication) throughout the study.', 'Subjects who experience a moderate or severe COPD exacerbation during the run-in', 'period will be deemed run-in failures. Subjects who experience a mild COPD', 'exacerbation, defined as worsening of symptoms that requires no treatment with', 'antibiotics or steroids and is self managed by the patient by an increase of inhaled rescue', 'medication, (Appendix 5), will be able to continue in the study based on the judgment of', \"the investigator and agreement of the sponsor's medical monitor.\", 'At the randomization Visit 2 (Day 1), those subjects who successfully complete the run-', 'in period as well as meet the other pre-defined eligibility and randomization criteria will', 'be randomized to one of the 3 treatment arms for 24 weeks.', 'In addition, a subset of subjects (approximately 150 per treatment arm) will undergo', 'assessment of their physical activity measured through a physical activity monitor', '(Actigraph GT9X) worn for 7 days from Screening (Visit 1), for 7 days from', 'Randomisation (Visit 2), 7 days from Visit 3, and for 7 days prior to last clinic Visit', '(Visit 5).', 'The occurrence of adverse events (AEs) will be evaluated throughout the study beginning', 'at Visit 2 (Day 1) and until the follow-up contact (Visit 6). Serious adverse events', '(SAEs) will be collected over the same time period as AEs. However, any SAEs', 'assessed as related to study participation (e.g., study treatment, protocol-mandated', 'procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant', 'medication, will be recorded from the time a subject consents to participate in the study', 'up to and including any follow up contact (Appendix 4).', 'All subjects will be given an electronic diary (eDiary) for use during the run-in, and the', 'treatment period to complete PRO questionnaires, record COPD daily symptoms, any', 'medical problems experienced during the study and the time they take their COPD', 'medications. Daily rescue medication usage (number of inhalations taken in the last 24h)', 'will also be captured in the eDiary. In addition, and in some countries, rescue medication', 'use will also be captured by the use of electronic metered dose inhaler (eMDI).', 'At Screening Visit 1, all subjects must be trained on the proper use of their existing', 'COPD medications inhalation devices and instructed to strictly adhere to and record the', 'time they take their COPD medications in the eDiary.', '20']\n\n###\n\n", "completion": "END"}